Bicycle Therapeutics PLC 10-Q quarterly reports

Bicycle Therapeutics plc announced its financial results for the second quarter ended June 30, 2026, highlighting a strategic reprioritization of its clinical portfolio and a workforce reduction.

Bicycle Therapeutics plc announced a strategic reprioritization of its clinical portfolio, focusing on nuzefatide pevedotin and next-generation Bicycle conjugates, alongside a workforce reduction of approximately 30%.

Bicycle Therapeutics plc reported increased net losses in Q3 2025, driven by substantial investments in clinical trials and R&D, alongside strategic cost reduction initiatives.

Bicycle Therapeutics plc reported a significantly wider net loss for the second quarter and first half of 2025, alongside a workforce reduction and decreased collaboration revenue, despite advancing its clinical pipeline.

Bicycle Therapeutics reports increased Q1 2025 net loss due to higher research and development expenses, while collaboration revenue declined.

Bicycle Therapeutics reports a net loss of $50.8 million for Q3 2024, while maintaining a robust cash balance of $890.9 million.

Bicycle Therapeutics reports a robust cash balance of $961.4 million after completing a significant private placement, while continuing to advance its clinical programs.

Bicycle Therapeutics reports a net loss of $26.6 million for the first quarter of 2024, with collaboration revenues increasing significantly due to progress in key partnerships.